Complex expression patterns of SATB family chromatin organizers as an improved biomarker tool for cancer prognosis

By analyzing the combined expression of SATB1 and SATB2 chromatin organizers, the method provides a reliable prognostic marker for cancer prognosis, addressing the lack of comprehensive understanding of their dual role in cancer progression across multiple cancer types.

JP7577061B2Active Publication Date: 2024-11-01
View PDF 5 Cites 0 Cited by

Patent Information

Application Number
JP2021530331
Authority / Receiving Office
JP · JP
Patent Type
Patents
Priority Date
2018-08-08
Filing Date
2019-08-08
Publication Date
2024-11-01
Estimated Expiration
2039-08-08

AI Technical Summary

Technical Problem

Existing studies have focused on the individual expression of SATB1 and SATB2 proteins in cancer, failing to provide insights into their combined expression pattern's role in cancer progression and prognosis across multiple cancer types.

Method used

Evaluating the dual expression pattern of SATB1 and SATB2 chromatin organizers using TCGA cancer patient survival data, assessing their combined expression levels through RNA sequencing and quantitative RT-PCR, and performing Kaplan-Meier survival analysis to determine their impact on cancer prognosis.

Benefits of technology

The dual expression pattern of SATB family chromatin organizers serves as a precise determinant of cancer patient survival, providing a reliable prognostic marker for various cancer types by revealing tumor-specific expression balances.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007577061000001
    Figure 0007577061000001
  • Figure 0007577061000002
    Figure 0007577061000002
  • Figure 0007577061000003
    Figure 0007577061000003
Patent Text Reader

Abstract

The present invention provides an in vitro method for assessing cancer aggressiveness and progression in multiple cancer types by profiling the combined expression pattern of SATB (Special AT-rich Sequence-Binding Protein) family chromatin organizers (i.e., SATB-1 and SATB-2) as a biomarker tool for cancer prognosis. The combined SATB expression pattern is defined by Kaplan-Meier survival analysis of patient datasets from multiple cancer types. Furthermore, the present invention provides a prognosis kit for assessing cancer progression by using the combined expression pattern of SATB1 and SATB-2 as a biomarker tool for cancer prognosis.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to a novel method for profiling a combined expression pattern of special AT-rich sequence-binding protein-1 (SATB) family chromatin organizers, namely SATB-1 and SATB-2, as a biomarker tool for cancer prognosis.

[0002] Furthermore, the present invention relates to a dual expression pattern of SATB proteins as an improved tool for the assessment of cancer aggressiveness and as a novel prognostic marker combination for multiple cancer types. [Background technology]

[0003] Cancer is a leading cause of death in India and worldwide. Cancer is a complex disease with multiple steps occurring through genetic alterations or abnormalities resulting in altered gene expression. For many cancer types, there is a lack of accurate prognostic biomarkers to assess the aggressiveness of the disease or progression of cancer.

[0004] Cancers are diverse with respect to their cellular origin and display dynamic molecular expression patterns influenced by the tissue microenvironment. This is a major limitation that leads to the failure of cancer treatment. There is a demand for accurate biomarkers to evaluate the aggressiveness of cancer. These prognostic markers would also evaluate the prognosis of the disease and drive cancer treatment decisions. In this context, the role of SATB family chromatin organizers has been implicated in cancer progression.

[0005] The SATB (special AT-rich binding protein) family proteins (SATB1 and SATB2) have emerged as key regulators orchestrating higher order chromatin organization with the control of gene expression. Research over the past decade has revealed the individual and specific roles of SATB1 and SATB2, two closely related members of this family, in cancer progression. SATB family chromatin organizers play diverse and critical roles in controlling the dynamic balance of apoptosis, cell invasion, metastasis, proliferation, angiogenesis, and immune regulation.

[0006] Many studies in the past decade have demonstrated a strong association between SATB1 expression and tumor aggressiveness in many cancer types. Mir et al. Oncogene 2016 published by the present inventors (Galande et al.) revealed the role of SATB1 in colorectal cancer tumorigenesis and tumor progression. The authors described a mechanistic understanding of the regulation of SATB1 and found that it is necessary and sufficient to regulate the expression of β-catenin, TCF family members, and multiple downstream effectors and mediators for the regulation of the Wnt signaling pathway.

[0007] Reference may be made to the study by Kohwi-Shigematsu et al. entitled "Cancer-associated mar binding protein," which suggested SATB1 as a diagnostic marker for T-cell leukemia (U.S. Patent No. 5,624,799). Abnormal expression of SATB1 is speculated to promote lymphoma (Agrelo et al. Dev. Cell. 2009) and cutaneous T-cell lymphoma (Fredholm et al. J Invest Dermatol. 2018; Sun et al. J Invest Dermatol. 2018).

[0008] Furthermore, in US Patent Application Publication No. 2015 / 0323536, Kohwi-Shigematsu et al. suggested a role for SATB1 in cancer metastasis in a study titled "SATB1: A Determinant of Morphogenesis and Tumor Metastasis."

[0009] In US Patent Application Publication No. 2017 / 067125, Kohwi-Shigematsu et al. also described the use of long non-coding RNAs targeting SATB1 as a therapeutic target for breast cancer cells, the study entitled "Long Non-Coding RNA Expressed in Aggressive Cancer." Zheng et al. showed that aberrant expression of SATB1 leads to breast tumor progression and metastasis.

[0010] Reference may also be made to US Patent No. 2018 / 0010195, in which Srivastava. S. describes the use of SATB1 as one of the markers in a panel for the assessment of cancer prognosis and diagnosis. The study is entitled "Compositions and methods for monitoring, diagnosis, prognosis, detection and treatment of cancer."

[0011] Furthermore, many studies have shown a correlation between cancer malignancy and SATB1 expression in the cases of nasopharynx (Deng et al., Int. J. Clin. Exp. Pathol. 2014), bladder (Han et al., Tumour Biol. 2013), prostate (Mao et al. J. Transl. Med. 2013; Wang et al. Exp Ther Med. 2018), lung (Selinger et al., J. Thorac. Oncol. 2011), ovary (Xiang et al., Oncol. Lett. 2012), liver (Tu et al., Liver Int. 2012), and glioma (Chu et al., J. Transl. Med. 2012).

[0012] Elebro et al. (J. Transl. Med. 2014) proposed SATB1 as a prognostic and predictive biomarker for both intestinal and pancreato-biliary type periampullary adenocarcinomas (including pancreatic cancer).

[0013] Feng et al. (Exp Ther Med. 2018) and Cheng et al. (PLoS One, 2014) showed a strong association of SATB1 with endometrial and renal cancer, respectively.

[0014] Regarding SATB2, its expression has been correlated with malignancy in colorectal cancer by Wang et al. (J. Pathol. 2009), bone cancer by Liu et al. (PLoS One, 2012), and head and neck cancer by Seong et al. (Oncogene, 2015), demonstrating a cancer-specific role.

[0015] A study by Uhlen et al., titled "Use of Protein SATB2 as a marker for Colorectal Cancer," proposed SATB2 alone as a diagnostic marker for colorectal cancer (U.S. Patent No. 8,465,934).

[0016] All of the above mentioned studies considered SATB1 or SATB2 individually and correlated their expression with tumor aggressiveness, however, these studies did not provide any indication of the significance of the dual expression pattern of SATB family chromatin organizers for their role in cancer progression and prognosis in multiple cancer types. [Prior art documents] [Patent documents]

[0017] [Patent Document 1] U.S. Patent No. 5,624,799 [Patent Document 2] US Patent Application Publication No. 2015 / 0323536 [Patent Document 3] US Patent Application Publication No. 2017 / 067125 [Patent Document 4] US Patent No. 2018 / 0010195 [Patent Document 5] U.S. Patent No. 8,465,934 Summary of the Invention [Problem to be solved by the invention]

[0018] The objective of this invention is to evaluate the dual expression of SATB family chromatin organizers in multiple cancer types and to determine the relationship of dual expression patterns to patient survival using TCGA (The Cancer Genome Atlas) cancer patient survival data to define cancer progression.

[0019] Another object of the present invention is to define the balance between expression patterns of SATB family chromatin organizers that are tumor type specific and act as determinants of cancer patient survival. [Means for solving the problem]

[0020] SATB family proteins have emerged as key regulators orchestrating higher order chromatin formation with the control of gene expression. Research over the past decade has revealed specific roles for SATB1 and SATB2, two closely related members of this family, in cancer progression. However, all studies performed to date have considered SATB1 and SATB2 in isolation.

[0021] In one aspect, the present invention provides an in-vitro method for assessing the progression and aggressiveness of cancer in a subject, characterized by assessing the combined expression pattern of SATB (Special AT-rich Sequence-Binding Protein) chromatin organizers (i.e., SATB-1 and SATB-2); i. culturing a tumorigenic cell culture isolated from a primary tumor tissue; and ii. assessing the combined expression levels of the SATB-1 and SATB-2 chromatin organizers in the cultures by RNA isolation and sequencing and quantitative RT-PCR. The present invention provides a method comprising:

[0022] In another aspect, the present invention provides a method for assessing dual expression patterns of SATB family chromatin organizers for cancer prognosis, comprising: (a) performing a Kaplan Meier survival analysis of a patient's TCGA (The Cancer Genome Atlas) dataset from multiple cancer types; and (b) comparing patient survival data with gene expression obtained through RNA sequencing of tumor samples from TCGA across multiple cancer types to assess the importance of SATB1 and SATB2 chromatin organizers to cancer prognosis; The present invention provides a method comprising:

[0023] In yet another aspect, the present invention provides a prognostic kit for assessing the progression of cancer in a subject by estimating the dual expression pattern of SATB family chromatin organizers for cancer prognosis, said kit comprising a table showing expression levels of SATB-1 and SATB-2 chromatin organizers in a plurality of cancer cell types, said table comprising expression levels of SATB-1 and SATB-2 chromatin organizers in a plurality of cancer cell types for comparison of the combined expression level of SATB-1 and SATB-2 in a patient tumor sample; (i) Increased combined expression of SATB-1 and SATB-2 strongly correlates with inferior patient survival for cervical squamous cell carcinoma, sarcoma, and gastric adenocarcinoma; (ii) expression of SATB1 negatively correlated with SATB2, resulting in inferior patient survival in colorectal adenocarcinoma (COAD), urothelial bladder carcinoma (URD), rectal adenocarcinoma (READ), lung squamous cell carcinoma, uterine corpus endometrial carcinoma, and liver hepatocellular carcinoma; (iii) Increased expression of SATB2 and decreased expression of SATB1 are determinants of inferior patient survival for acute myeloid leukemia, low-grade glioma, cutaneous melanoma, and pancreatic adenocarcinoma (Figure 1; Figure 2).

[0024] The table showing the combined expression levels of SATB1 and SATB2 in multiple cancer cell types is set forth in FIG.

[0025] In another aspect, the present invention provides tissue-specific expression patterns of SATB1 and SATB2 chromatin organizers in 3D spheroid cultures and 2D cell lines, and the combined expression of said SATB chromatin family organizers serves as a highly reliable tool to accurately predict tumor aggressiveness.

[0026] The present invention also demonstrates the functional importance of expression of SATB family chromatin organizers, whereby an in vitro model of tumor-initiating cells, three-dimensional (3D) spheroid cultures, was established.

[0027] More preferably, the expression patterns of SATB family chromatin organizers in spheroids (3D culture) and cell lines (2D culture) generated from colon cancer cell lines were profiled. Upregulation of SATB1 in spheroids and downregulation in 2D cultures were observed, and SATB2 was highly expressed in 2D cultures compared to 3D spheroid cultures, thus suggesting a role for dynamic expression of SATB family chromatin organizers in controlling cell plasticity.

[0028] Thus, the present invention convincingly demonstrates that there is a dynamic balance between the expression patterns of the SATB1 and SATB2 chromatin organizers that is tumor type specific and serves as a precise determinant of cancer patient survival. [Brief description of the drawings]

[0029] [Figure 1] Plot of Kaplan-Meier analysis of SATB1 expression in various cancer types. Red lines indicate high expression of SATB1, while blue lines indicate low expression of SATB1. Data are plotted for urothelial bladder cancer, cervical squamous cell carcinoma, glioblastoma, kidney renal clear cell carcinoma, kidney renal papillary cell carcinoma, acute myeloid leukemia, low-grade glioma, liver hepatocellular carcinoma, lung adenocarcinoma, lung squamous cell carcinoma, ovarian cancer, pancreatic adenocarcinoma, sarcoma, cutaneous melanoma, gastric adenocarcinoma, uterine endometrial carcinoma, colon adenocarcinoma, rectal adenocarcinoma, and invasive breast cancer. Statistical significance was calculated using a log-rank p-value ≤ 0.05. $ refers to datasets with smaller number of patients with p-value ≤ 0.1. [Diagram 2] Plot of Kaplan-Meier analysis of SATB2 expression in various cancer types. Red lines indicate high expression of SATB2, while blue lines indicate low expression of SATB2. Data are plotted for urothelial bladder cancer, cervical squamous cell carcinoma, glioblastoma, renal clear cell carcinoma, papillary renal cell carcinoma, acute myeloid leukemia, low-grade glioma, liver hepatocellular carcinoma, lung adenocarcinoma, lung squamous cell carcinoma, ovarian cancer, pancreatic adenocarcinoma, sarcoma, cutaneous melanoma, gastric adenocarcinoma, uterine endometrial carcinoma, colorectal adenocarcinoma, rectal adenocarcinoma, and invasive breast cancer. Statistical significance was calculated using a log-rank p-value ≤ 0.05. $ indicates dataset with smaller number of patients with p-value ≤ 0.1. [Diagram 3] FIG. 3 depicts the relationship of expression of SATB family chromatin organizers to patient survival across cancer types. [Figure 4] SATB family chromatin organizers show dynamic regulation in 2D and 3D (spheroid) cultures. A, Representative images of 7-day 3D (spheroids) generated from colon cancer cell lines Ai HCT116, A-ii HT29, and A-iii HCT15. B, Graphical representation of relative gene expression of SATB1 (Bi) and SATB (B-ii) in HCT116, HCT15, and HT29 colon cancer cell lines (2D) and spheroids (3D) by quantitative RT-PCR analysis, with actin expression used as an endogenous control. (*, P<0.05; **, P<0.001; ***, P<0.0001). [Diagram 5] Spheroids show a self-renewing compartment with increased expression of pluripotency markers and decreased expression of differentiation markers.Graphical representation of quantitative RT-PCR of A-differentiation markers (CK20 and cyclin E1); B-pluripotency markers (Nanog, Klf4, Oct4, and Sox2) in HCT116, HCT15, and HT29 colon cancer cell lines (2D) and spheroids (3D), where actin expression was used as an endogenous control. (*, P<0.05; **,P<0.001; ***, P<0.0001). DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0030] The present invention has been described in detail, with reference to certain preferred and best embodiments, so that various aspects can be fully understood and appreciated.

[0031] The aberrant expression of SATB family chromatin organizers and their association with multiple cancer cell types suggests their involvement in regulating higher order chromatin formation leading to carcinogenesis. SATB proteins provide a structural network that controls multiple genes, and thus aberrant expression of SATB may lead to an accumulation of molecular events that result in tumorigenesis.

[0032] In a preferred embodiment, the present invention provides an in-vitro method for assessing the progression and aggressiveness of cancer in a subject, characterized by assessing the combined expression pattern of SATB (Special AT-rich Sequence-Binding Protein) chromatin organizers (i.e. SATB-1 and SATB-2); (i) culturing a tumorigenic cell culture isolated from a primary tumor tissue; and (ii) assessing the combined expression levels of the SATB-1 and SATB-2 chromatin organizers in the cultures by RNA isolation and sequencing, quantitative RT-PCR, immunohistochemistry, and immunoblotting. The present invention provides a method comprising:

[0033] The techniques of RNA isolation and sequencing, quantitative RT-PCR, immunohistochemistry, and immunoblotting are well established in the art and therefore can be performed.

[0034] The method provides for assessing the extent and aggressiveness of cancer in cancer cell types selected from the group including urothelial bladder cancer, cervical squamous cell carcinoma, glioblastoma, renal clear cell carcinoma, papillary renal cell carcinoma, papillary renal cell carcinoma, acute myeloid leukemia, low-grade glioma, liver hepatocellular carcinoma, lung adenocarcinoma, lung squamous cell carcinoma, ovarian cancer, pancreatic adenocarcinoma, sarcoma, cutaneous melanoma, gastric adenocarcinoma, uterine endometrial carcinoma, colon adenocarcinoma, rectal adenocarcinoma, and invasive breast carcinoma.

[0035] In one embodiment, the present invention provides a method for defining dual expression patterns of SATB family chromatin organizers in a number of cancers for cancer prognosis derived from patient survival data, the method comprising: (a) performing a Kaplan-Meier survival analysis of patient TCGA (The Cancer Genome Atlas) datasets from multiple cancer types and comparing patient survival data with primary tumor gene expression obtained through RNA sequencing analysis of the TCGA dataset; (b) correlating the gene expression of the SATB-1 and SATB-2 chromatin organizers obtained through the RNA sequencing of step (a) to evaluate the significance of the gene expression of the SATB-1 and SATB-2 chromatin organizers to the prognosis of cancer. Includes.

[0036] The first step involved performing a Kaplan-Meier survival analysis of the relationship of expression of SATB1 and SATB2 family chromatin organizers to patient survival across multiple tumor types. TCGA data was used to evaluate the association of intratumoral SATB chromatin organizer expression with patient survival across multiple tumor types. A survival analysis of the TCGA dataset of patients from 14 cancer types, where gene expression obtained through RNA sequencing correlates with patient survival data, was performed to evaluate the importance of the two members of the SATB family chromatin organizers to cancer prognosis. Based on gene expression (normalized RSEM RNAseqV2 read counts), patients were classified from highest to lowest. The top 15%-25% and bottom 15%-25% of patients based on SATB1 expression were significantly higher in SATB1 than in SATB2. hi and SATB1 low Similarly, based on gene expression profiles, patients were characterized as SATB2 hi and SATB2 low The significance of SATB chromatin organizer was classified as significant or insignificant. Statistical significance was calculated using a log-rank p-value ≤ 0.05, which was considered significant. However, because an increase in the number of patients would lead to an increase in the importance of the study, those cancer types with a smaller number of patients were included in the survival analysis (p-value ≤ 0.1) if they followed the survival / trend. Survival studies clearly revealed that the SATB chromatin organizer exhibits dynamic expression patterns, tissue-specific regulation, and is a determinant of patient survival.

[0037] The cancer cell types analyzed to define the dual expression pattern of SATB family chromatin organizers are selected from the group including urothelial bladder cancer, cervical squamous cell carcinoma, glioblastoma, renal clear cell carcinoma, papillary renal cell carcinoma, papillary renal cell carcinoma, acute myeloid leukemia, low-grade glioma, liver hepatocellular carcinoma, lung adenocarcinoma, lung squamous cell carcinoma, ovarian cancer, pancreatic adenocarcinoma, sarcoma, cutaneous melanoma, gastric adenocarcinoma, uterine endometrial carcinoma, colon adenocarcinoma, rectal adenocarcinoma, and invasive breast cancer.

[0038] In a preferred embodiment, the present invention provides a relationship between the expression status of both SATBl and SATB2 and cancer type, which serves as a highly reliable prognostic marker, as defined by Kaplan-Meier analysis based on patient survival data.

[0039] The invention provides for comparing the expression patterns to a table showing expression levels of SATB-1 and SATB-2 chromatin organizers in multiple cancer cell types, said table comprising: i. increased combined expression of SATB1 and SATB2 correlates with inferior patient survival in cervical squamous cell carcinoma, sarcoma, and gastric adenocarcinoma; ii. Increased expression of SATB1, combined with decreased expression of SATB2, results in inferior patient survival in urothelial bladder cancer, colorectal adenocarcinoma (COAD), rectal adenocarcinoma (READ), lung squamous cell carcinoma, uterine endometrial carcinoma, and liver hepatocellular carcinoma; and iii. In acute myeloid leukemia, low-grade glioma, cutaneous melanoma, and pancreatic adenocarcinoma, increased expression of SATB2 and decreased expression of SATB1 were determinants of inferior patient survival (Figure 1; Figure 2). Includes.

[0040] In another embodiment, the present invention provides that increased combined expression of SATB-1 and SATB-2 in tumor samples compared to healthy tissue correlates with poor patient survival in cervical squamous cell carcinoma, sarcoma, and gastric adenocarcinoma.

[0041] In yet another embodiment, the present invention provides that increased expression of SATB1, accompanied by decreased SATB2, in tumor samples compared to healthy tissue correlates with poor patient survival in urothelial bladder cancer, colorectal adenocarcinoma (COAD), rectal adenocarcinoma (READ), lung squamous cell carcinoma, uterine endometrial carcinoma, and liver hepatocellular carcinoma.

[0042] In another embodiment, the present invention provides that increased expression of SATB2 and decreased expression of SATB1 in tumor samples compared to healthy tissue correlates with poor patient survival in acute myeloid leukemia, low-grade glioma, cutaneous melanoma, and pancreatic adenocarcinoma.

[0043] Thus, the above table showing the combined expression levels of SATB-1 and SATB-2 in multiple cancer cell types is set forth in Figure 3. The present method for assessing the progression of cancer by determining the combined expression levels of SATB-1 and SATB-2 in a particular cancer cell type is an accurate and precise method.

[0044] In another preferred embodiment, the present invention provides the functional consequences associated with the expression of SATB family chromatin organizers with regard to tumor regenerative potential.

[0045] The present invention provides the use of an in-vitro method for assessing the progression and aggressiveness of cancer types selected from the group consisting of urothelial bladder cancer, cervical squamous cell carcinoma, glioblastoma, renal clear cell carcinoma, papillary renal cell carcinoma, papillary renal cell carcinoma, acute myeloid leukemia, low-grade glioma, liver hepatocellular carcinoma, lung adenocarcinoma, lung squamous cell carcinoma, ovarian cancer, pancreatic adenocarcinoma, sarcoma, skin melanoma, gastric adenocarcinoma, uterine endometrial cancer, colorectal adenocarcinoma, rectal adenocarcinoma, and invasive breast cancer, wherein upon determining the combined expression pattern of SATB-1 and SATB-2 in tumorigenic cells isolated from the primary tumor tissue of a subject / patient diagnosed with cancer, the risk of the subject or patient is inferred as follows; (i) Increased combined expression of SATB1 and SATB2 correlates with inferior patient survival in cervical squamous cell carcinoma, sarcoma, and gastric adenocarcinoma; (ii) increased expression of SATB1, combined with decreased expression of SATB2, results in inferior patient survival in urothelial bladder cancer, colorectal adenocarcinoma (COAD), rectal adenocarcinoma (READ), lung squamous cell carcinoma, uterine endometrial carcinoma, and liver hepatocellular carcinoma; and (iii) In acute myeloid leukemia, low-grade glioma, cutaneous melanoma, and pancreatic adenocarcinoma, increased expression of SATB2 and decreased expression of SATB1 were determinants of inferior patient survival.

[0046] In a preferred embodiment, an in-vitro method for assessing the progression and aggressiveness of colorectal cancer / colon adenocarcinoma / rectal adenocarcinoma in a patient is provided, characterized by assessing the combined expression pattern of SATB (Special AT-rich Sequence-Binding Protein) chromatin organizers (i.e. SATB-1 and SATB-2), comprising: (i) culturing a tumorigenic cell culture isolated from a primary tumor tissue; and (ii) assessing the combined expression levels of the SATB-1 and SATB-2 chromatin organizers in the cultures by RNA isolation and sequencing, quantitative RT-PCR, immunohistochemistry, and immunoblotting. The present invention provides a method comprising: detecting a combination of SATB expression patterns in tumorigenic cells cultured as 3D spheroids, where increased expression of SATB-1, accompanied by decreased expression of SATB-2, results in inferior patient survival in patients diagnosed with colorectal cancer / colon adenocarcinoma / rectal adenocarcinoma.

[0047] Figure 4 shows increased expression levels of SATB1 and decreased expression levels of SATB-2 in colon cancer cell lines cultured as spheroid cultures. Thus, this in-vitro method is a robust method for assessing patient survival by determining SATB expression.

[0048] Thereby, the present invention provides a method for profiling the complex expression patterns of SATB (Special AT-rich Sequence-Binding Protein) family chromatin organizers (i.e. SATB-1 and SATB-2) as a biomarker tool for cancer prognosis with proof of principle based on functional assays in in-vitro studies, comprising: (a) establishing 3D and 2D cultures from cancer cell lines; and (b) profiling gene expression patterns of SATB family chromatin organizers in spheroids (3D culture) and cell lines (2D culture) produced from the cancer cell lines using quantitative RT-PCR; The present invention provides a method comprising:

[0049] In this context, spheroids (3D cultures) from colon cancer cell lines, which are an established functional model for studying neoplastic cells, were generated and the expression of SATB1 and SATB2 in 3D cultures was evaluated. Spheroids essentially involve the functional isolation of tumor initiating cells (TICs) or neoplastic cells that depend on various characteristics (e.g., anchorage-independent growth, chemotherapeutic drug resistance, self-renewal, asymmetric division, and pluripotency). Spheroids reflect the 3D cellular context and associated pathophysiological gradients of in vivo tumors. Thus, spheroids (3D) are a suitable in vitro model system for evaluating the malignancy of cancer.

[0050] SATB1 was found to be positively regulated in spheroid cultures and negatively regulated in cell lines, while SATB2 was negatively regulated in 3D cultures compared to 2D cultures, suggesting that there is a balance between the expression of SATB chromatin organizers that governs cellular and molecular functions within tumors.

[0051] In another preferred embodiment, the present invention provides a kit for assessing the progression of cancer in a subject by predicting the dual expression pattern of SATB family chromatin organizers for cancer prognosis, comprising a table showing the expression levels of SATB-1 and SATB-2 chromatin organizers in multiple cancer cell types.

[0052] The prognostic kit of the present invention for assessing the progression and aggressiveness of a cancer type and predicting survival in a subject diagnosed with cancer comprises: (i) Healthy cell cultures as a negative control (ii) cancer type-specific tumorigenic cell cultures as positive controls; (iii) tools for performing RNA isolation, sequencing, and RT-PCR; and (iv) A table showing the combined expression patterns of SATB1 and SATB2 specific to cancer type, showing: (a) Increased combined expression of SATB1 and SATB2 correlates with inferior patient survival in cervical squamous cell carcinoma, sarcoma, and gastric adenocarcinoma; (b) increased expression of SATB1, together with decreased expression of SATB2, correlates with inferior patient survival in urothelial bladder cancer, colorectal adenocarcinoma (COAD), rectal adenocarcinoma (READ), lung squamous cell carcinoma, uterine endometrial carcinoma, and liver hepatocellular carcinoma; and (iii) Increased expression of SATB2 and decreased expression of SATB1 correlate with inferior patient survival in acute myeloid leukemia, low-grade glioma, pancreatic adenocarcinoma, and cutaneous melanoma.

[0053] In line with the above-mentioned embodiments and the in-vitro method, the present invention provides tumorigenic cell lines (positive control) and healthy cell cultures (negative control) specific to the type of cancer to be evaluated in patients for aggressiveness and progression. Alternatively, the in-vitro method can be performed by directly using patient-derived tissue (i.e., biopsy samples). The RNA isolation and sequencing steps are performed according to methods known in the art and can be performed by a person skilled in the art. Upon determining the expression of SATB-1 and SATB-2 in the test sample, the expression patterns against a table representing the above patterns are analyzed in relation to patient survival.

[0054] Thus, the present methods, showing the combined expression pattern of SATB1 and SATB2, provide improved insight into understanding tumor progression, and thus define the combined expression pattern of SATB1 and SATB2 as a reliable prognostic marker. EXAMPLES

[0055] The following examples are given by way of illustration of the invention and therefore should not be construed as limiting the scope of the invention.

[0056] Example 1: SATB chromatin organizer as a biomarker for cancer prognosis Survival analysis revealed that higher expression of both SATB1 and SATB2 correlated with poorer patient survival in cervical squamous cell carcinoma, sarcoma, and gastric adenocarcinoma. Correlation of SATB1 has been linked to aggressiveness in gastric adenocarcinoma and cervical squamous cell carcinoma by Wang et al Jpn J Clin Oncol. 2015 and Hedner et al Virchows Arch. 2014, however, none of these studies reported association of SATB2. These findings are in agreement with earlier reports in sarcoma by Wang et al Tumour Biol. 2015, Zhang et al Mol Cell Biochem. 2013, and Liu et al Mol Cell Biochem. 2017, where in independent studies, expression of SATB1 and SATB2, respectively, correlated with tumor aggressiveness.

[0057] SATB1 expression negatively correlates with SATB2 and results in poor patient survival in colorectal adenocarcinoma (COAD), rectal adenocarcinoma (READ), lung squamous cell carcinoma, uterine endometrial carcinoma, and liver hepatocellular carcinoma (summarized in Table 1), the first two cancer types speculated by Brocato et al. (Carcinogenesis, 2015) and Tsuji et al. (Cancer Res. 2009), while the correlation with the latter type is novel. Survival analysis revealed that higher expression of SATB2 and lower expression of SATB1 are determinants of poor patient survival in acute myeloid leukemia, low-grade glioma, urothelial bladder cancer, and pancreatic adenocarcinoma (Figure 1; Figure 2). However, recent studies have shown a lack of clarity regarding the correlation of SATB1 expression with respect to urothelial bladder cancer (Choudhary et al. Urol Oncol. 2018). Surprisingly, higher expression of both SATB proteins conferred better patient survival in renal clear cell carcinoma. This analysis is consistent with established facts of downregulation of both SATB chromatin organizers in renal clear cell carcinoma by Kowalczyk et al. (Cancer Genomics Proteomics, 2016) and Guo et al. (Int J Clin Exp Pathol. 2015). Thus, the analysis presented here clearly indicates tissue-specific regulation of SATB chromatin organizers in relation to tumor aggressiveness. This comprehensive analysis across multiple tumor types, which can be effectively used to design molecular targeted therapies, strongly supports the use of both members of the SATB family chromatin organizers to classify cancer types.

[0058] Example 2: SATB family chromatin organizers show dynamic regulation in colorectal cancer. Source of biological material: The HCT116 and HCT15 cell lines were obtained from the European Collection of Cell Cultures (ECACC, SIGMA, St. Louis, USA), and the HT29 cell line was obtained from the American Type Culture Collection (ATCC, Mansas, Virginia, USA).

[0059] Special AT-rich binding protein (SATB) family proteins have emerged as key regulators orchestrating higher-order chromatin formation with the control of gene expression. Recent studies have demonstrated that both SATB1 and SATB2 are instrumental for cancer progression. However, no studies to date have performed extensive characterization of both members of the SATB family chromatin organizers with respect to their role in colorectal cancer malignancy.

[0060] To evaluate the regulation of the SATB chromatin organizer in terms of regenerative potential, 3D spheroid cultures (Fig. 4A-i, Bi, Ci) from colon cancer cell lines were established. Spheroids were generated 7 days after plating single colon cancer cells on ultra-low attachment plates. Spheroids and corresponding cell lines were subjected to RNA isolation and profiled for expression of the SATB chromatin organizer using qRT-PCR. A dramatic increase in expression of SATB1, whereas a clear decrease in SATB2, was observed in spheroid cultures compared to the respective cell lines (Fig. 4Bi, B-ii). Thus, expression of SATB1 positively correlated with the spheroid phenotype, an in vitro model for the assessment of malignant potential of cancer cells. Conversely, expression of SATB2 negatively correlated with spheroids.

[0061] To further understand the function, the expression of pluripotency markers (Nanog, Klf4, Oct4, Sox2) and differentiation markers (CK20 and cyclinE1) across spheroids and corresponding 2D cell line cultures was assessed. Spheroids exhibited a cell fraction involved in self-renewal and therefore showed upregulation of all pluripotency markers and corresponding downregulation of differentiation markers compared to the respective cell lines (Figure 4A, B). This data suggests a dynamic regulation of the SATB chromatin organizer on cellular plasticity, with SATB1 involved in the generation and maintenance of a self-renewal state. The expression of SATB2 correlated with CK20 and cyclinE1 suggests that SATB2 may be involved in mediating differentiation of colon cancer cells.

[0062] This example clearly demonstrates distinct functions regulated by two members of the SATB family of chromatin organizers involved in colon cancer progression.

[0063] Advantages of the invention: The present invention provides a dynamic balance between expression patterns of SATB family chromatin organizers that are tumor type specific and act as determinants of survival in cancer patients. Cancer tissue-specific regulation of SATB family chromatin organizers serves as an accurate biomarker for cancer prognosis. Improved assessment of cancer aggressiveness.

Claims

1. 1. An in-vitro method for assessing the progression and aggressiveness of cancer in a subject, characterized by assessing the combined expression level of SATB-1 and SATB-2 (Special AT-rich Sequence-Binding Protein) chromatin organizers, comprising: i. culturing a tumorigenic cell culture isolated from a primary tumor tissue; and ii. assessing the combined expression patterns of the SATB-1 and SATB-2 chromatin organizers in the cultures by RNA isolation and quantitative RT-PCR. wherein the tumorigenic cells are cultured as 3D spheroid cultures; The combined expression levels of SATB-1 and SATB-2 are assessed for cancers selected from the group including cervical squamous cell carcinoma, sarcoma, gastric adenocarcinoma, urothelial bladder cancer, colorectal adenocarcinoma (COAD), rectal adenocarcinoma (READ), lung squamous cell carcinoma, uterine endometrial cancer, liver hepatocellular carcinoma, acute myeloid leukemia, low-grade glioma, pancreatic adenocarcinoma, and cutaneous melanoma; An in-vitro method, wherein assessing the combined expression pattern of SATB-1 and SATB-2 is selected from the group comprising: (i) Increased combined expression of SATB1 and SATB2 correlates with inferior patient survival in cervical squamous cell carcinoma, sarcoma, and gastric adenocarcinoma; (ii) increased expression of SATB1, together with decreased expression of SATB2, correlates with inferior patient survival in colorectal adenocarcinoma (COAD), rectal adenocarcinoma (READ), lung squamous cell carcinoma, uterine endometrial carcinoma, and liver hepatocellular carcinoma; and (iii) Increased expression of SATB2 and decreased expression of SATB1 correlate with inferior patient survival in urothelial bladder cancer, acute myeloid leukemia, low-grade glioma, pancreatic adenocarcinoma, and cutaneous melanoma.

2. A prognostic kit for assessing the type, progression and aggressiveness of cancer in a subject diagnosed with cancer, for use in the in vitro method of claim 1, comprising: (i) Healthy cell cultures as a negative control (ii) cancer type-specific tumorigenic cell cultures as positive controls; (iii) tools for performing RNA isolation, sequencing, and RT-PCR; and (iv) A table showing the combined expression patterns of SATB1 and SATB2 specific to cancer type, showing: (a) Increased combined expression of SATB1 and SATB2 correlates with inferior patient survival in cervical squamous cell carcinoma, sarcoma, and gastric adenocarcinoma; (b) increased expression of SATB1, together with decreased expression of SATB2, correlates with inferior patient survival in colorectal adenocarcinoma (COAD), rectal adenocarcinoma (READ), lung squamous cell carcinoma, uterine endometrial carcinoma, and liver hepatocellular carcinoma; and (c) Increased expression of SATB2 and decreased expression of SATB1 correlate with inferior patient survival in urothelial bladder cancer, acute myeloid leukemia, low-grade glioma, pancreatic adenocarcinoma, and cutaneous melanoma.

Citation Information

Patent Citations

  • SATB1: a determinant of morphogenesis and tumor metastatis

    US20150323536A1

  • Long non-coding RNA expressed in aggressive cancer

    US20170067125A1

  • Compositions and methods for monitoring, diagnosis, prognosis, detection, and treatment of cancer

    US20180010195A1

  • Cancer-associated mar binding protein

    US5624799A

  • Use of protein SATB2 as a marker for colorectal cancer

    US8465934B2